



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/670,568	01/18/2001	Yoji Ikawa	Q61014	5597
7590 08/18/2005		EXAMINER		
Sughrue Mion Zinn			YU, MISOOK	
Macpeak & Seas 2100 Pennsylvania Avenue NW Washington, DC 20037-3202			ART UNIT	PAPER NUMBER
			1642	
		DATE MAILED. 00/10/2005		

DATE MAILED: 08/18/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.	Applicant(s)	
09/670,568	IKAWA ET AL.	
Examiner	Art Unit	
MISOOK YU, Ph.D	1642	

Advisory Action Before the Filing of an Appeal Brief --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 03 May 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. X The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: The period for reply expires months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b), ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on 03 June 2005. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: . (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 112, second paragraph. 6. Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. Tor purposes of appeal, the proposed amendment(s): a) uill not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: 3 and 24. Claim(s) objected to: Claim(s) rejected: 1.2 and 16-22. Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. 

The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). 13. 

☐ Other: interview summary.

U.S. Patent and Trademark Office PTOL-303 (Rev. 4-05)

Continuation of 11. does NOT place the application in condition for allowance because: Claims 2 and 19 remain rejected under 35 U.S.C. 102(b) as being anticipated by GenEmbl accession number Y114146 (Sep. 02, 1997) as evidenced by Kaghad et al (IDS, Cell vol. 90, pages 809-19). Claims 2 and 19 are drawn to an isolated DNA molecule that hybridizes to the protein coding region of SEQ ID NO:2 under the recited condition wherein said DNA encodes a protein apoptosis inducing activity, wherein claim 19 is drawn to cDNA. Applicant argues the art does not teach the protein of the prior art of record has apoptosis inducing activity of the amended claims 2, and 19. This argument is persuasive because the apoptosis inducing activity is the inherent activity of the prior art of record resulting from the transcriptional activity of the protein which in turn leads to growth inhibition of cells due to apoptosis (cell death).

Claims 1, 16, 17, and 22 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. Applicant argues that the specification as originally filed has support for the 50 % homology to the full-length sequence. This argument has been fully considered but found unpersuasive. Although the specification discloses where in the protein of SEQ ID NO: 1 lies the claimed transcription activation, DNA binding, and oligomerization domains and the recited functional characteristics of transcriptional control, growth inhibition and/or apoptosis induction are not associated with any specific domains of SEQ ID NO: 1, but the recited functional characteristics are associated with the full length protein sequence, which the instant base claim 1 recites only 50% homology.